These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4005121)

  • 1. Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form.
    Jack DB; Kendall MJ; Laugher SJ; Smith SR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):185S-190S. PubMed ID: 4005121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.
    Bradbrook ID; John VA; Morrison PJ; Rogers HJ; Spector RG
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):163S-169S. PubMed ID: 4005118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations.
    John VA; Smith SE
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):191S-195S. PubMed ID: 4005122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacokinetics of oxprenolol following oral and rectal dosing--a comparison of delivery systems and routes of administration.
    Gregg MR; Jack DB; Smith SR; Kendall MJ
    J Clin Pharm Ther; 1987 Apr; 12(2):91-9. PubMed ID: 3584272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.
    Woods KL; Jack DB; Kendall MJ; Halsey A; O'Donnell ML; Warrington SJ; John VA
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):177S-184S. PubMed ID: 4005120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations.
    Langenbucher F; Mysicka J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):151S-162S. PubMed ID: 4005117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-dose pharmacokinetic and pharmacodynamic comparison of polymer-matrix (Slow Trasicor) and Oros dosage forms of oxprenolol in healthy volunteers.
    Bennett PN; Bennett J; Bradbrook I; Francis J; John VA; Rogers H; Turner P; Warrington SJ
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):171S-175S. PubMed ID: 4005119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects.
    Bradbrook ID; Babiker M; Crome P; Gillies HC; Morrison PJ; Rogers HJ; Shotton P
    Br J Clin Pharmacol; 1986 Apr; 21(4):371-6. PubMed ID: 3707811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report.
    John VA; Shotton PA; Moppert J; Theobald W
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):203S-206S. PubMed ID: 4005123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.
    Davis SS; Washington N; Parr GD; Short AH; John VA; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1988 Oct; 26(4):435-43. PubMed ID: 3056482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers.
    Moppert J; Degen PH; Racine-Poon A
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):197S-201S. PubMed ID: 2988591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of oxprenolol and metoprolol Oros systems in the dog: comparison of in vivo and in vitro drug release, and of drug absorption from duodenal and colonic infusion sites.
    Fara JW; Myrback RE; Swanson DR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):91S-95S. PubMed ID: 4005134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.
    Antonin KH; Bieck P; Scheurlen M; Jedrychowski M; Malchow H
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):137S-142S. PubMed ID: 4005115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of site of drug delivery on the systemic availability of metoprolol: comparison of intragastric infusion and 14/190 Oros administration.
    Warrington SJ; Barclay SP; John VA; Shotton PA; Wardle HM; Good W
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):219S-224S. PubMed ID: 4005126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osmotically controlled-delivery of metoprolol in man: in vivo performance of Oros systems with different durations of drug release.
    Godbillon J; Gerardin A; Richard J; Leroy D; Moppert J
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):213S-218S. PubMed ID: 4005125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of two oxprenolol oral osmotic (OROS) delivery systems in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Eur J Clin Pharmacol; 1988; 34(6):605-11. PubMed ID: 3169112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers.
    Wilding IR; Davis SS; Hardy JG; Robertson CS; John VA; Powell ML; Leal M; Lloyd P; Walker SM
    Br J Clin Pharmacol; 1991 Nov; 32(5):573-9. PubMed ID: 1954073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily.
    Müller FB; Allsopp LF; Cooper GL; Bolli P; Frei P; Glaus L; Ritz R; Bühler FR
    Br J Clin Pharmacol; 1985; 19 Suppl 2(Suppl 2):207S-212S. PubMed ID: 4005124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects.
    West MJ; Kendall MJ; Mitchard M; Faragher EB
    Br J Clin Pharmacol; 1976 Jun; 3(3):439-43. PubMed ID: 788749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-effect relationships for oxprenolol in patients with essential hypertension.
    McInnes GT; Brodie MJ
    Br J Clin Pharmacol; 1988 May; 25(5):539-45. PubMed ID: 3408634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.